奈他地爾二甲磺酸鹽 Netarsudil Dimesylate

一、產品概述

      Netarsudil Dimesylate由Aerie Pharmaceuticals開發(fā)，作為青光眼或高眼壓的用藥，于2017年12月18日獲得美國食品藥品管理局（FDA）批準上市，化合物專利2026年到期。

二、主要產品

Description	Structural   Formula	CAS No.	Category
Netarsudil Dimesylate		1422144-42-0	API
(S)-3-((tert-butoxycarbonyl)amino)-2-(4-(((2,4-dimethylbenzoyl)oxy)methyl)phenyl)propanoic       acid		2097334-20-6	Intermediate
isoquinolin-6-amine		23687-26-5	Intermediate
(R)-4-(2-(4-benzyl-2-oxooxazolidin-3-yl)-2-oxoethyl)benzyl     2,4-dimethylbenzoate		2097334-18-2	Intermediate
(S)-4-(3-((tert-butoxycarbonyl)amino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl       2,4-dimethylbenzoate		1253955-19-9	Intermediate

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.